Skip to content

US · ANL · BIOTECHNOLOGY

Adlai Nortye Ltd. (ANL) intrinsic value and stock valuation

$8.55as of 2026-11-21 · Mkt cap 693.76M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Adlai Nortye Ltd. DCF and intrinsic value

InvestorsCraft values ANL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ANL’s statements →

Adlai Nortye Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Grand Cayman KY1-1104 adlainortye.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$5M
20192025
Net income
-$-35.53M
20192025
Free cash flow
-$-33.73M
20192025
Total equity
-$-8.32M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$5M$0.00$0.00$0.00$45.7M
Operating income-$-35.7M-$-52.93M-$-72.55M-$-67.27M-$-8.65M
Net income-$-35.53M-$-51.87M-$-109.23M-$-58.79M-$-56.68M
EPSd-$-3.33M-$-4.87M-$-16.06M-$-6.93M-$-6.68M
Operating cash flow-$-33.54M-$-51.82M-$-56.65M-$-43.22M-$-3.03M
Capital expenditure-$-190K-$-170K-$-200K-$-1.27M-$-1.12M
Free cash flow-$-33.73M-$-51.99M-$-56.85M-$-44.49M-$-4.15M
Total assets$34.4M$71.3M$130.2M$72.6M$131.7M
Total debt$26.4M$27.2M$31.6M$6.54M$13.4M
Net debt$2.59M-$-33.68M-$-59.94M-$-36.21M-$-50.79M
Total equity-$-8.32M$25.5M$75.1M-$-241.29M-$-185.43M
Cash and short-term investments$23.8M$60.9M$98.5M$64.1M$117.9M
Income statement
20252024202320222021
Revenue$5M$0.00$0.00$0.00$45.7M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$5M$0.00$0.00$0.00$45.7M
Research and development expenses$32.8M$44.9M$58.2M$54.5M$42.1M
Selling, general and administrative expenses$7.79M$9.44M$14.8M$12.4M$12.5M
Other expenses$80K-$-1.43M-$-420K$350K-$-180K
Operating expenses$40.7M$52.9M$72.6M$67.3M$54.4M
Cost and expenses$40.7M$52.9M$72.6M$67.3M$54.4M
Interest income$0.00$0.00$60K$550K$30K
Interest expense$1.49M$1.94M$790K$430K$1.34M
Depreciation and amortization$1.41M$1.87M$2.22M$2.04M$1.83M
Ebitda-$-32.63M-$-48.05M-$-106.22M-$-56.32M-$-53.51M
Operating income-$-35.7M-$-52.93M-$-72.55M-$-67.27M-$-8.65M
Total other income/expenses, net$170K$1.06M-$-36.68M$8.48M-$-48.03M
Income before tax-$-35.53M-$-51.87M-$-109.23M-$-58.79M-$-56.68M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-35.53M-$-51.87M-$-109.23M-$-58.79M-$-56.68M
Weighted average shares outstanding$10.7M$10.6M$6.8M$8.48M$8.48M
Weighted average diluted shares outstanding$10.7M$10.6M$6.8M$8.48M$8.48M
Balance sheet
20252024202320222021
Cash and short-term investments$23.8M$60.9M$98.5M$64.1M$117.9M
Net receivables$1.39M$1.17M$360K$350K$1.93M
Inventory$0.00$0.00$0.00-$0.00$0.00
Total current assets$26.9M$64.1M$101.2M$66.3M$124.5M
Property, plant and equipment, net$3.02M$2.71M$3.8M$5.88M$6.59M
Goodwill and intangible assets$20K$40K$60K$90K$100K
Long-term investments$4.25M$4.16M$24.9M$0.00$0.00
Total non-current assets$7.54M$7.21M$29M$6.29M$7.14M
Total assets$34.4M$71.3M$130.2M$72.6M$131.7M
Accounts payable$12.6M$10.2M$14.4M$13.1M$2.98M
Short-term debt$25.3M$26.8M$31.1M$5.31M$11.3M
Deferred revenue$0.00$5M$0.00$3.88M$0.00
Total current liabilities$41.6M$45.4M$49.7M$312.7M$17.5M
Long-term debt$1.13M$420K$470K$1.24M$2.05M
Deferred revenue, non-current$0.00$0.00$5M$0.00$0.00
Total non-current liabilities$1.13M$420K$5.47M$1.24M$299.6M
Capital lease obligations$1.13M$900K$1.19M$2.24M$2.89M
Total liabilities$42.8M$45.8M$55.1M$313.9M$317.1M
Common stock$10K$10K$10K$0.00$0.00
Retained earnings-$-464.85M-$-429.32M-$-373.09M-$-268.22M-$-209.43M
Accumulated other comprehensive income (loss)$17.3M-$-4.54M-$-4.24M$9.53M-$-1M
Total equity-$-8.32M$25.5M$75.1M-$-241.29M-$-185.43M
Total investments$4.25M$4.16M$31.9M$21.3M$53.8M
Total debt$26.4M$27.2M$31.6M$6.54M$13.4M
Net debt$2.59M-$-33.68M-$-59.94M-$-36.21M-$-50.79M
Cash flow statement
20252024202320222021
Net income-$-35.62M-$-51.87M-$-104.87M-$-58.79M-$-56.68M
Depreciation and amortization$1.42M$1.87M$2.22M$2.04M$1.83M
Stock-based compensation$0.00$2.45M$4.33M$6.08M$3.39M
Change in working capital-$-2.29M-$-5.54M$6.12M$15.3M$250K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$2.5M-$-4.2M$1.25M$10.1M$600K
Net cash provided by operating activities-$-33.54M-$-51.82M-$-56.65M-$-43.22M-$-3.03M
Investments in property, plant and equipment-$-190K-$-170K-$-200K-$-1.27M-$-1.12M
Acquisitions, net$0.00-$-4.21M$0.00-$0.00-$-100K
Net cash used for investing activities-$-15.62M$28.1M-$-10.95M$28.4M-$-54.86M
Common stock issued$0.00$150K$91.8M$0.00$97.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-3.82M-$-6.58M$116.2M-$-6.78M$97.2M
Net change in cash-$-37.12M-$-30.59M$48.7M-$-21.37M$39.9M
Cash at end of period$23.8M$60.9M$91.5M$42.8M$64.1M
Operating cash flow-$-33.54M-$-51.82M-$-56.65M-$-43.22M-$-3.03M
Capital expenditure-$-190K-$-170K-$-200K-$-1.27M-$-1.12M
Free cash flow-$-33.73M-$-51.99M-$-56.85M-$-44.49M-$-4.15M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Adlai Nortye Ltd.

        Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.

        CEO
        Yang Lu
        Employees
        109
        Beta
        1.16

        Explore

        Frequently asked questions

        What is the intrinsic value of Adlai Nortye Ltd. (ANL)?

        InvestorsCraft does not currently publish an intrinsic value for ANL. How the IC value is calculated.

        Is ANL undervalued?

        InvestorsCraft does not publish an undervaluation signal for ANL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.